Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | NJH395 |
Synonyms | |
Therapy Description |
NJH395 comprises an Erbb2 (Her2) antibody linked to a TLR7/8 agonist, which potentially increases anti-tumor immune response against tumor cells expressing Erbb2 (Her2) (Journal for ImmunoTherapy of Cancer 2020;8). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NJH395 | NJH 395|NJH-395|anti-HER2 ISAC NJH395 | HER2 (ERBB2) Antibody 72 | NJH395 comprises an Erbb2 (Her2) antibody linked to a TLR7/8 agonist, which potentially increases anti-tumor immune response against tumor cells expressing Erbb2 (Her2) (Journal for ImmunoTherapy of Cancer 2020;8). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03696771 | Phase I | NJH395 | Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer | Completed | USA | ITA | 2 |